Search

everythinglearnresearchcommunity

for

Search:↓

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

Bimekizumab effectively treats scalp cellulitis and improves quality of life.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Co-trimoxazole may help treat autoimmune diseases.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Targeting abnormal lung fluid metabolism could reduce COVID-19 deaths and ventilator use.

There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.

Men have higher COVID-19 mortality rates than women due to biological and lifestyle factors.

COVID-19 infection may cause significant hair loss, but full hair recovery is likely without special treatment.

COVID-19 temporarily affects male reproductive health, but sperm and testosterone levels generally return to normal after three months.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Organoids can help study COVID-19 and develop treatments, but face challenges like instability and limited renewal.

Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.